ClinConnect ClinConnect Logo
Search / Trial NCT06901102

Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial

Launched by MANSOURA UNIVERSITY · Mar 23, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Bee Venom Mineral Bone Disorder Hemodialysis Immunomodulation Regulatory T Cells Bone Turnover Markers

ClinConnect Summary

This clinical trial is studying the effects of bee venom injections as a potential treatment for mineral bone disorders in patients with chronic kidney disease who are on hemodialysis. Mineral bone disorder is a common issue for these patients, often leading to problems with bone health and increased risks for heart disease. The researchers want to find out if bee venom can help improve the balance of important minerals in the body and enhance bone health, possibly offering a new treatment option for those facing these challenges.

To participate in this study, individuals must be at least 18 years old and have been receiving hemodialysis three times a week for at least six months. They should not be planning to have a kidney transplant within the next year. Participants will receive either bee venom injections or standard care treatments and will be monitored to see how their condition changes over time. This trial is currently not recruiting, but it aims to provide valuable insights into a new approach that could improve patient outcomes and quality of life for those dealing with chronic kidney disease-related bone issues.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients of both sexes aged 18 years and older.
  • Patients undergoing maintenance hemodialysis three times weekly for at least six months.
  • Patients who are not scheduled for kidney transplantation within the next year.
  • Exclusion Criteria:
  • Current pregnancy or lactation.
  • Medical history of chronic conditions such as liver disease, cancer, or autoimmune diseases.
  • Refusal to participate in the study.
  • Active chronic infections, including HIV, HCV, HBV, and tuberculosis.
  • Current use of medications affecting bone metabolism (e.g., calcitonin, denosumab, estrogen) within the last six months.
  • History of renal allograft failure within the past year.

About Mansoura University

Mansoura University is a prestigious academic institution located in Egypt, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of healthcare to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a network of healthcare professionals and researchers to conduct high-quality clinical trials, focusing on addressing critical health challenges through rigorous scientific methodologies. Its dedication to ethical research practices and adherence to regulatory standards underscores its role as a leader in the medical research community.

Locations

Mansoura, Dakahliya, Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported